Intravenous diazepam application in a departmental convulsive status epilepticus protocol with CYP2C19 polymorphisms: a pediatric prospective cohort study.

While Type 2 Diabetes Mellitus (T2DM) has historically been managed as a chronic, progressive condition requiring lifelong medication, contemporary clinical evidence has shifted the focus toward metabolic remission []. T2DM remission—defined as achieving sub-diagnostic glycemic levels without active pharmacological intervention—is now recognized as a primary clinical endpoint that can arrest the progression of complications []. However, the physiological mechanisms and predictors of early remission are often studied in Western populations, leaving a critical gap in understanding how these trajectories manifest in sub-Saharan African cohorts []. Recent landmark studies, such as the Diabetes Remission Clinical Trial (DiRECT), have demonstrated that significant weight loss and intensive glycemic management can lead to T2DM reversal [, ] Despite these global advancements, there is limited evidence regarding the durability of remission in resource-limited settings. In the African context, unique factors such as dietary transitions, varying genetic predispositions, and differences in healthcare delivery systems may alter the expected time to first remission [, ]. Investigating these patterns is essential to validate international remission protocols within diverse clinical environments. In Ethiopia, the escalating burden of T2DM poses a substantial threat to a healthcare system already strained by a dual burden of infectious and chronic diseases []. This study is particularly significant for Ethiopia as it provides facility-based evidence from Eastern Ethiopia to inform national treatment guidelines. Identifying local prognostic factors for remission is a matter of economic and clinical urgency; it offers a pathway to reduce long-term dependency on costly medications and minimize the socioeconomic impact of diabetes-related disability. By tailoring management strategies to the Ethiopian clinical context, healthcare providers can prioritize metabolic recovery over lifelong disease maintenance. T2DM can cause a variety of severe consequences [, ]. It can lead to serious health complications including heart disease, stroke, nerve damage, foot problems, vision loss, kidney disease, sexual problems, increased risk of miscarriage and stillbirth, weakened immune function, reduced respiratory function, and depression, in addition to common symptoms such as excessive thirst, frequent urination, and tiredness []. Furthermore, The present prevalence of T2DM and its projected rise create a huge public health challenge increasing diabetes-related healthcare expenditures [, ]. Healthcare expenditures for individuals with T2DM are projected to be significantly higher in 2040 compared to those without diabetes, with costs driven by factors such as medication costs, advanced age, high literacy, higher income, longer disease duration, multiple complications, and the use of combination therapies [].